Giorgio Croci

Dr. Giorgio Croci

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FPFabio Pagni
Fabio Pagni
ERElena Guerini Rocco
Elena Guerini Rocco
ASAnne Maria Schultheis
Anne Maria Schultheis
GGGiulia Grazia
Giulia Grazia
ERErika Rijavec
Erika Rijavec
Nicola FuscoNicola Fusco
Nicola Fusco
Immunotherapy has become the standard-of-care in many solid tumors. Despite the significant recent achievements in the diagnosis and treatment of cancer, several issues related to patients’ selection for immunotherapy remain unsolved. Multiple lines of evidence suggest that, in this setting, the vision of a single biomarker is somewhat naïve and imprecise, given that immunotherapy does not follow the rules that we have experienced in the past for targeted therapies. On the other hand, additional immune-related biomarkers that are reliable in real-life clinical practice remain to be identified. Recently, the immune-checkpoint blockade has been approved in the US irrespective of the tumor site of origin. Further histology-agnostic approvals, coupled with with tumor-specific companion diagnostics and guidelines, are expected in this field. In addition, immune-related biomarkers can also have a significant prognostic value. In this review, we provide an overview of the role of these biomarkers and their characterization in the management of lung cancer, melanoma, colorectal cancer, gastric cancer, head and neck cancer, renal cell carcinoma, urothelial cancers, and breast cancer.

14 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DDDhouha Dridi
Dhouha Dridi
FCFrancesca Chiaffarino
Francesca Chiaffarino
Fabio ParazziniFabio Parazzini
Fabio Parazzini
ADAgnese Donati
Agnese Donati
Laura BuggioLaura Buggio
Laura Buggio
PVPaolo Pietro Vercellini
Paolo Pietro Vercellini
Umbilical endometriosis represents 30–40% of abdominal wall endometriosis and around 0.5–1.0% of all cases of endometriosis. The aim of this systematic review is to revisit the epidemiology, signs, and symptoms and to formulate a pathogenic theory based on literature data. We performed a systematic literature review using the PubMed and Embase databases from 1 January 1950 to 7 February 2021, according to the PRISMA guidelines. The review was registered at PROSPERO (CRD42021239670). Studies were selected if they reported original data on umbilical endometriosis nodule defined at histopathological examination and described as the presence of endometrial glands and/or stromal cells in the connective tissue. A total of 11 studies (10 retrospective and one prospective), and 14 case series were included in the present review. Overall, 232 umbilical endometriosis cases were reported, with the number per study ranging from 1 to 96. Umbilical endometriosis was observed in 76 (20.9%; 95% CI 17.1–25.4) of the women included in studies reporting information on the total number of cases of abdominal wall endometriosis. Umbilical endometriosis was considered a primary form in 68.4% (158/231, 95% CI 62.1–74.1) of cases. A history of endometriosis and previous abdominal surgery were reported in 37.9% (25/66, 95% CI 27.2–49.9) and 31.0% (72/232, 95% CI 25.4–37.3) of cases, respectively. Pain was described in 83% of the women (137/165, 95% CI 76.6–88.0), followed by catamenial symptoms in 83.5% (142/170, 95% CI, 77.2–88.4) and bleeding in 50.9% (89/175, 95% CI 43.5–58.2). In the 148 women followed for a period ranging from three to 92.5 months, seven (4.7%, 95% CI 2.3–9.4) recurrences were observed. The results of this analysis show that umbilical endometriosis represents about 20% of all the abdominal wall endometriotic lesions and that over two thirds of cases are primary umbilical endometriosis forms. Pain and catamenial symptoms are the most common complaints that suggest the diagnosis. Primary umbilical endometriosis may originate from implantation of regurgitated endometrial cells conveyed by the clockwise peritoneal circulation up to the right hemidiaphragm and funneled toward the umbilicus by the falciform and round liver ligaments.

12 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Marco Pizzi, MD PhDMarco Pizzi, MD PhD
Marco Pizzi, MD PhD
GCGiorgio Croci
Giorgio Croci
MRMarco Ruggeri
Marco Ruggeri
STSilvia Maria Tabano
Silvia Maria Tabano
ATAngelo Paolo Dei Tos
Angelo Paolo Dei Tos
UGUmberto Gianelli
Umberto Gianelli
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of clonal hematopoietic stem cell disorders, characterized by increased proliferation of one or more myeloid lineages in the bone marrow. The classification and diagnostic criteria of MPNs have undergone relevant changes over the years, reflecting the increased awareness on these conditions and a better understanding of their biological and clinical-pathological features. The current World Health Organization (WHO) Classification acknowledges four main sub-groups of MPNs: (i) Chronic Myeloid Leukemia; (ii) classical Philadelphia-negative MPNs (Polycythemia Vera; Essential Thrombocythemia; Primary Myelofibrosis); (iii) non-classical Philadelphia-negative MPNs (Chronic Neutrophilic Leukemia; Chronic Eosinophilic Leukemia); and (iv) MPNs, unclassifiable (MPN-U). The latter are currently defined as MPNs with clinical-pathological findings not fulfilling the diagnostic criteria for any other entity. The MPN-U spectrum traditionally encompasses early phase MPNs, terminal (i.e., advanced fibrotic) MPNs, and cases associated with inflammatory or neoplastic disorders that obscure the clinical-histological picture. Several lines of evidence and clinical practice suggest the existence of additional myeloid neoplasms that may expand the spectrum of MPN-U. To gain insight into such disorders, this review addresses the history of MPN classification, the evolution of their diagnostic criteria and the complex clinical-pathological and biological features of MPN-U.

1 November 2021 in Annals of Oncology
Verified
Journal Article
Closed access
GCGiorgio Croci
Giorgio Croci
RAR.K.H. Au-Yeung
R.K.H. Au-Yeung
SRS. Reinke
S. Reinke
ASA.M. Staiger
A.M. Staiger
KKK. Koch
K. Koch
WKW. Klapper
W. Klapper

14 February 2018 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
RCRachele Ciccocioppo
Rachele Ciccocioppo
GCGiorgio Croci
Giorgio Croci
FBFederico Biagi
Federico Biagi
AVAlessandro Vanoli
Alessandro Vanoli
CACostanza Alvisi
Costanza Alvisi
GCGino R. Corazza
Gino R. Corazza

23 January 2020 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
GCGiorgio Croci
Giorgio Croci
EHEva Hoster
Eva Hoster
SBSílvia Beà
Sílvia Beà
GCGuillem Clot
Guillem Clot
AEAnna Enjuanes
Anna Enjuanes
WKWolfram Klapper
Wolfram Klapper